An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023.
BMC Cancer. 2018 Jul 31;18(1):771. doi: 10.1186/s12885-018-4505-4.
BMC Cancer. 2018.
PMID: 30064406
Free PMC article.
Clinical Trial.